Meituan Breaks Record in Instant Retail, Late-Night Orders Fuel Growth

美团即时零售刷新纪录，夜宵订单成增长新引擎

According to internal sources, Meituan’s instant retail orders surpassed 120 million by 10:54 PM on July 5.

据美团内部消息，截至7月5日晚上10时54分，当日即时零售订单量已突破1.2亿单。

Over 100 million of those were food-related, showing strong consumer demand.

其中餐饮类订单超过1亿单，展现出强劲的消费需求。

Late-night orders during the weekend played a key role in this growth.

特别是在周末的夜宵时段，订单量增长显著。

Instant retail has become an essential part of daily life for many users.

即时零售已成为许多用户日常生活的重要组成部分。

Experts believe this segment still has strong growth potential.

业内人士认为，该领域未来仍具备可观增长空间。

Shanghai LEGOLAND Opens with Summer Dining Discounts to Attract Tourists

上海乐高乐园盛大开园，夏季推半价餐饮吸客

Shanghai LEGOLAND Resort officially opened to the public on July 5, 2025.

2025年7月5日，上海乐高乐园正式对外开放。

The resort includes both a theme park and a hotel, with plans to expand over the next 5–10 years.

该度假区包含主题乐园和酒店，未来5至10年还将计划扩展。

To celebrate the opening, the park offers 50% off dining in July and August.

为庆祝开园，乐园在7月至8月推出餐饮半价优惠。

The promotion aims to enhance visitor experience and boost foot traffic.

此举旨在提升游客体验并吸引更多客流。

LEGOLAND is expected to become a major family destination in the Yangtze River Delta.

乐高乐园有望成为长三角地区的重要亲子旅游目的地。

China's U19 Basketball Team Wins First World Cup Game, Zhang and Yang Shine

U19男篮迎来世界杯首胜，张博源杨溢表现亮眼

China's U19 men’s basketball team beat Jordan 97-78 for their first World Cup victory.

中国U19男篮以97比78战胜约旦，赢得本届世界杯首场胜利。

They started strong with a 29-17 lead in the first quarter and extended it to 23 points in the second.

中国队开局强势，首节以29比17领先，第二节一度扩大至23分优势。

Zhang Boyuan scored 22 points and 8 rebounds, while Yang Yi delivered 17 assists despite not scoring.

张博源砍下22分8篮板，杨溢虽未得分却送出17次助攻。

Though their offense slowed in the final quarter, China maintained control to win by 19 points.

尽管末节进攻放缓，中国队仍以19分优势锁定胜局。

The victory boosts morale and strengthens hopes of advancing.

这场胜利提升了士气，也增强了晋级希望。

Chinese Innovative Drugs Gain Global Momentum, Market Reacts Positively

国产创新药捷报频传，市场积极反应看好前景

Dizal Pharma’s drug “Sunvozertinib” was approved by the U.S. FDA—the first of its kind globally.

中国迪哲医药的“舒沃哲”获得美国FDA批准，成为首个在美获批的全球首创新药。

It targets advanced non-small cell lung cancer with EGFR Exon20ins mutations and shows strong efficacy.

该药针对EGFR Exon20ins突变型晚期非小细胞肺癌，展现出良好疗效。

Meanwhile, Genor Biopharma’s GR1803 was approved for clinical trials, and Sunshine Guohao teamed up with Lepu for new pain treatments.

与此同时，智翔金泰的GR1803注射液获批临床，阳光诺和与乐旷惠霖合作开发新镇痛药。

The news sent innovation drug stocks soaring, with several hitting the daily limit.

受此利好，创新药板块多只个股涨停。

Analysts say upcoming changes to the drug reimbursement catalog could further support commercialization.

分析指出，医保目录调整将为创新药商业化提供更多支持。